Geneos Therapeutics: Raises $12M in Series A1 Financing

March 10, 2021

796

Geneos Therapeutics: Raises $12M in Series A1 Financing

Must read

Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

Geneos Therapeutics, Pa.-based clinical stage company, closed its Series A1 round, raising $12m in financing
The round led by Korea Investment Partners– Global Bio Fund with participation from existing investors Santé Ventures and Inovio Pharmaceuticals, Inc
In conjunction with the financing, Mr. Sangwoo Lee, Managing Director Korea Investment Partners USA Inc. joined Geneos’ Board of Directors
Geneos Therapeutics also develops personalized therapies for cancer using its GT-EPIC™ platform to target unique neoantigens from individual patient tumors
The company’s GT-EPIC Neoantigen-Targeting Platform is based on a clinically-validated DNA medicines technology exclusively licensed from Inovio Pharmaceuticals, Inc